Other metrics of response, including clinical measures, such as eosinophilia and sites of metastatic disease, have also been observed in studies on the anti-PD-1 therapy drug pembrolizumab, but these metrices are not in routine clinical use [87,88]. This evidence concerns the gene PDCD1 and metastatic neoplasm.